St. Jude Medical (STJ) 10-Q 7 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Apr. 04, 2015	1-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	4-Apr-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	ST JUDE MEDICAL INC
Entity Central Index Key	203077
Current Fiscal Year End Date	-1
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		281,177,315

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Earnings (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014
Income Statement [Abstract]
Net sales	$1,345	$1,363
Cost of sales:
Cost of sales before special charges	393	382
Special charges	2	1
Total cost of sales	395	383
Gross profit	950	980
Selling, general and administrative expense	430	444
Research and development expense	167	170
Amortization of intangible assets	24	21
Special charges	4	33
Operating profit	325	312
Interest income	-1	-1
Interest expense	21	21
Other (income) expense	-3	0
Other expense, net	17	20
Earnings before income taxes and noncontrolling interest	308	292
Income tax expense	52	53
Net earnings before noncontrolling interest	256	239
Less: Net loss attributable to noncontrolling interest	-6	-10
Net earnings attributable to St. Jude Medical, Inc.	$262	$249
Net earnings per share attributable to St. Jude Medical, Inc.:
Basic	$0.93	$0.88
Diluted	$0.91	$0.86
Cash dividends declared per share:	$0.29	$0.27
Weighted average shares outstanding:
Basic	283	284.4
Diluted	287.1	289.3

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014
Statement of Comprehensive Income [Abstract]
Net earnings before noncontrolling interest	$256	$239
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Unrealized gain (loss) on available-for-sale securities	1	0
Unrealized gain (loss) on derivative financial instruments, net of taxes of $5 million	29	0
Foreign currency translation adjustment	-127	10
Other comprehensive income (loss), net of tax	-97	10
Total comprehensive income before noncontrolling interest	159	249
Total comprehensive loss attributable to noncontrolling interest	-6	-10
Total comprehensive income attributable to St. Jude Medical, Inc.	$165	$259

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015
Statement of Comprehensive Income [Abstract]
Tax expense (benefit) on related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges	$5

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Apr. 04, 2015	Jan. 03, 2015
In Millions, unless otherwise specified
ASSETS
Cash and cash equivalents	$695	$1,442
Accounts receivable, less allowance for doubtful accounts of $52 million and $53 million at April 4, 2015 and January 3, 2015, respectively	1,194	1,215
Finished goods	536	543
Work in process	82	77
Raw materials	190	164
Inventories	808	784
Other current assets	496	473
Total current assets	3,193	3,914
Property, plant and equipment, at cost	2,741	2,775
Less: Accumulated depreciation	-1,433	-1,432
Net property, plant and equipment	1,308	1,343
Goodwill	3,509	3,532
Intangible assets, net	825	851
Other assets	579	567
TOTAL ASSETS	9,414	10,207
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current debt obligations	1,737	1,593
Accounts payable	208	151
Income taxes payable	72	60
Other current liabilities	749	862
Total current liabilities	2,766	2,666
Long-term debt	1,767	2,273
Other liabilities	999	1,024
Total liabilities	5,532	5,963
Commitments and Contingencies (Note 4)	0	0
Shareholders’ Equity
Preferred stock ($1.00 par value; 25,000,000 shares authorized; none outstanding)	0	0
Common stock ($0.10 par value; 500,000,000 shares authorized; 280,199,780 and 286,659,901 shares issued and outstanding at April 4, 2015 and January 3, 2015, respectively)	28	29
Additional paid-in capital	10	118
Retained earnings	4,075	4,225
Accumulated other comprehensive income (loss)	-270	-173
Total shareholders' equity before noncontrolling interest	3,843	4,199
Noncontrolling interest	39	45
Total shareholders’ equity	3,882	4,244
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$9,414	$10,207

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Apr. 04, 2015	Jan. 03, 2015
In Millions, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable allowance for doubtful accounts	$52	$53
Preferred stock, par value	$1	$1
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred Stock Shares Outstanding	0	0
Common stock, par value	$0.10	$0.10
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	280,199,780	286,659,901
Common stock, shares outstanding	280,199,780	286,659,901

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014
OPERATING ACTIVITIES
Net earnings before noncontrolling interest	$256	$239
Adjustments to reconcile net earnings before noncontrolling interest to net cash from operating activities:
Depreciation of property, plant and equipment	54	55
Amortization of intangible assets	24	21
Stock-based compensation	17	17
Deferred income taxes	-13	16
Other, net	-32	-8
Changes in operating assets and liabilities, net of business combinations:
Accounts receivable	-47	67
Inventories	-46	-65
Other current and noncurrent assets	2	13
Accounts payable and accrued expenses	-6	-103
Income taxes payable	25	21
Net cash provided by operating activities	234	273
INVESTING ACTIVITIES
Purchases of property, plant and equipment	-33	-46
Proceeds from sale of investments	0	4
Other investing activities, net	-1	0
Net cash used in investing activities	-34	-42
FINANCING ACTIVITIES
Proceeds from exercise of stock options and stock issued, net	38	60
Excess tax benefits from stock issued under employee stock plans	5	9
Common stock repurchased, including related costs	-500	-476
Dividends paid	-77	-72
Issuances (payments) of commercial paper borrowings, net	390	326
Payments under debt facilities	-750	0
Other financing activities, net	-6	-6
Net cash used in financing activities	-900	-159
Effect of currency exchange rate changes on cash and cash equivalents	-47	1
Net increase (decrease) in cash and cash equivalents	-747	73
Cash and cash equivalents at beginning of period	1,442	1,373
Cash and cash equivalents at end of period	$695	$1,446

Basis_Of_Presentation

Basis Of Presentation	3 Months Ended
	Apr. 04, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis Of Presentation	BASIS OF PRESENTATION
	Principles of Consolidation: The accompanying unaudited Condensed Consolidated Financial Statements of St. Jude Medical, Inc. (St. Jude Medical or the Company) have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (U.S. generally accepted accounting principles) for complete financial statements. In the opinion of management, these statements include all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s consolidated results of operations, financial position and cash flows. The Condensed Consolidated Balance Sheet at January 3, 2015 was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements. Operating results for any interim period are not necessarily indicative of the results that may be expected for the full year. Preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the financial statements and footnotes. Actual results could differ from those estimates. This Quarterly Report on Form 10-Q should be read in conjunction with the Company’s consolidated financial statements and footnotes included in its Annual Report on Form 10-K for the fiscal year ended January 3, 2015.
	The unaudited Condensed Consolidated Financial Statements include the accounts of the Company, its wholly-owned subsidiaries for which St. Jude Medical has a controlling financial interest and variable interest entities (VIEs) where St. Jude Medical is the primary beneficiary. The Company operates as a single operating segment and derives its revenues from six principal product categories.
	Fiscal Year: We utilize a 52/53-week fiscal year ending on the Saturday nearest December 31st. Each of the three-month periods ended April 4, 2015 and March 29, 2014 included 13 weeks.
	Reclassifications: Certain prior period amounts have been reclassified to conform to current year presentation.
	New Accounting Pronouncements: In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will supersede the current revenue recognition requirements. The amendments in ASU 2014-09 are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are evaluating our approach to the adoption and the potential impact to our results of operations and financial position. The Company will adopt the new guidance beginning in fiscal year 2017.
	In February 2015, the FASB issued ASU No. 2015-02 (ASU 2015-02), Consolidation (Topic 810): Amendments to the Consolidation Analysis, which affects both the variable interest entity and voting interest entity consolidation models. The amendments in ASU 2015-02 are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is, however, permitted. The Company is evaluating its approach to the adoption and the potential impact to its results of operations and financial position.
	In April 2015, the FASB issued ASU No. 2015-03 (ASU 2015-03), Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The amendments in ASU 2015-03 are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years, with retrospective application required. Early adoption is, however, permitted. The Company is evaluating the timing of adoption and the potential impact to its financial position.
	In April 2015, the FASB issued ASU No. 2015-04 (ASU 2015-04), Compensation-Retirement Benefits (Topic 715): Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets, which permits entities to measure defined benefit plan assets and obligations using the month-end that is closest to the entity’s fiscal year-end and apply that practical expedient consistently from year to year. The amendments in ASU 2015-04 are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years, with prospective application required. Early adoption is, however, permitted. The Company plans to elect the accounting policy prospectively in accordance with ASU 2015-04 by using December 31 when it performs its measurements as of January 2, 2016 and for all fiscal years thereafter. The Company does not expect the adoption of this ASU to have a material impact on the Company’s results of operations or financial condition.
	In April 2015, the FASB issued ASU No. 2015-05 (ASU 2015-05), Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement, which provides guidance to customers about how to account for cloud computing arrangements when such arrangements include software licenses. The amendments in ASU 2015-05 are effective for annual periods beginning after December 15, 2015, and interim periods within those fiscal years, with either retrospective application or prospective transition permitted. Early adoption is, however, permitted. The Company is evaluating the timing of adoption and the potential impact to its results of operations and financial condition.

Business_Combinations_and_Vari

Business Combinations and Variable Interest Entities	3 Months Ended
	Apr. 04, 2015
Business Combinations [Abstract]
Business Combinations and Variable Interest Entities	BUSINESS COMBINATIONS AND VARIABLE INTEREST ENTITIES
	Spinal Modulation: In June 2013, the Company made an equity investment of $40 million in Spinal Modulation, Inc. (Spinal Modulation) a privately-held company that is focused on the development of an intraspinal neuromodulation therapy that delivers spinal cord stimulation targeting the dorsal root ganglion to manage chronic pain. The investment agreement resulted in a 19% voting equity interest and provided the Company with the exclusive right, but not the obligation, to acquire Spinal Modulation for payments of up to $300 million during the period that extends through the completion of certain regulatory milestones. Additionally, in connection with the investment and contingent acquisition agreement, the Company also entered into an exclusive international distribution agreement, and obtained significant decision-making rights over Spinal Modulation's operations and economic performance. At the time of the initial agreement, the Company also committed to providing additional debt financing to Spinal Modulation of up to $15 million. Accordingly, effective June 7, 2013, the Company determined that Spinal Modulation was a VIE for which St. Jude Medical was the primary beneficiary with the financial condition and results of operations of Spinal Modulation included in St. Jude Medical's Condensed Consolidated Financial Statements. Through April 4, 2015, the Company had increased the available financing to Spinal Modulation to $25 million, and as of April 4, 2015, Spinal Modulation had utilized $20 million of the total available financing. The following table summarizes Spinal Modulation’s assets and liabilities included in St. Jude Medical Inc.'s consolidated balance sheet as of April 4, 2015 after elimination of all intercompany balances and transactions (in millions):
		4-Apr-15
	Cash and cash equivalents	$	9
	Other current assets	7
	Goodwill	46
	In-process research and development (IPR&D)	45
	Other intangible assets	7
	Total assets	$	114
	Current liabilities	$	7
	Deferred income taxes	19
	Total liabilities	$	26
	Non-controlling interest	$	39
	The Company has had a 19% voting equity interest in Spinal Modulation and allocated the losses attributable to Spinal Modulation's noncontrolling shareholders to noncontrolling interest in St. Jude Medical's Condensed Consolidated Statements of Earnings and Condensed Consolidated Balance Sheets. On May 1, 2015, the Company exercised its exclusive option to acquire the remaining ownership interest in Spinal Modulation (see Notes 3 and 7).

Debt

Debt	3 Months Ended
	Apr. 04, 2015
Debt Disclosure [Abstract]
Debt	DEBT
	The carrying value of the Company’s debt, including discounts, the fair value of an interest rate swap agreement and the remaining deferred gain from a terminated interest rate swap agreement, consisted of the following (in millions):
		April 4, 2015			January 3, 2015
	Term loan due June 2015	$	—		$	500
	Term loan due August 2015	—			250
	2.50% senior notes due 2016	504			506
	3.25% senior notes due 2023	897			896
	4.75% senior notes due 2043	696			696
	1.58% Yen-denominated senior notes due 2017	68			68
	2.04% Yen-denominated senior notes due 2020	106			107
	Yen-denominated credit facilities	54			54
	Commercial paper borrowings	1,179			789
	Total debt	3,504			3,866
	Less: current debt obligations	1,737			1,593
	Long-term debt	$	1,767		$	2,273
	Contractual maturities of the Company's debt for the next five fiscal years and thereafter, excluding discounts, the fair value of an interest rate swap agreement and the remaining deferred gain from a terminated interest rate swap agreement, as of April 4, 2015 are as follows (in million):
		Remainder of 2015		2016			2017		2018		2019		After 2019
	Expected future minimum principal payments	$	1,206	$	527		$	68	$	—	$	—	$	1,707
	During the first quarter of 2015, the Company repaid its 2-year, $500 million unsecured term loan due June 2015 and its 364-day, $250 million unsecured term loan due August 2015. The Company also increased its commercial paper balance to support the Company’s common stock repurchases during the first quarter of 2015. Refer to Note 7 for further information on the Company's common stock repurchase.
	The yen-denominated credit facility that expired in March 2015 for 3.25 billion Japanese Yen (the equivalent of $27 million as of April 4, 2015) was automatically extended for a one-year period bearing interest at Yen LIBOR plus 0.25%.
	On May 1, 2015, the Company entered into a 364-day, $175 million unsecured term loan that matures in April 2016, the proceeds of which were used to acquire the remaining ownership interest in Spinal Modulation. These borrowings bear interest at LIBOR plus 0.9% and the Company may repay the term loan at any time.

Commitments_And_Contingencies

Commitments And Contingencies	3 Months Ended
	Apr. 04, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	COMMITMENTS AND CONTINGENCIES
	Product Liability Litigation
	Riata® Litigation: On December 17, 2014, the Company entered into an agreement that establishes a private settlement program to resolve the actions, disputes and claims-both filed and unfiled-of certain claimants against St. Jude Medical, Inc. relating to its Riata® and Riata® ST Silicone Defibrillation Leads. The agreement was entered into with a group of counsel representing plaintiffs in proceedings in jurisdictions around the country as well as claimants with Riata leads who have not initiated litigation. St. Jude Medical, Inc. accrued $15 million in the fourth quarter of 2014 to fund the settlement, which resolved approximately 950 of the outstanding, pending cases and claims. The terms of the agreement provide that, under certain circumstances, the Company can elect to terminate the settlement program and exercise its “walk away” right. The time period in which eligible claimants can submit their documentation to participate in the settlement closed during the first quarter of 2015.
	Most of the resolved lawsuits were brought by single plaintiffs, but some of them named multiple individuals as plaintiffs. Among the resolved lawsuits are eight separate multi-plaintiff lawsuits filed from April 2013 through October 2014 in both the state and federal courts of California that involved 173 unrelated claimants.
	Although the majority of the claimants in the aforementioned suits and claims identified no specific injuries, some of the claimants alleged bodily injuries as a result of surgical revision or removal and replacement of Riata® leads, or other complications, which they attribute to the leads. The majority of the claimants who sought recovery for implantation and/or surgical removal of Riata® leads sought compensatory damages in unspecified amounts, and declaratory judgments that the Company is liable to them for any past, present and future evaluative monitoring, and corrective medical, surgical and incidental expenses and losses. Several claimants also sought punitive damages.
	As of May 1, 2015, the Company is aware of four lawsuits, of more than 70 filed as of December 17, 2014, which were filed by plaintiffs in the U.S. alleging injuries caused by, and asserting product liability claims concerning, Riata® and Riata® ST Silicone Defibrillation Leads where counsel for the claimant has advised that the claimant will not participate in the above-described settlement program. The four remaining lawsuits are pending in the state courts of Georgia, Illinois, Kentucky and South Carolina.
	In November 2013, an amended claim was filed in a Canadian proposed class proceeding alleging that Riata® leads were prone to insulation abrasion and breach, failure to warn and conspiracy. The plaintiffs took no action between their 2008 filing and the amended claim they filed in November 2013. The Company has filed its statement of intent to defend in response to the amended claims, and the plaintiffs have not taken any further action.
	The Company is financially responsible for legal costs incurred in the continued defense of the Riata product liability claims, including any potential settlements, judgments and other legal defense costs. The Company believes that a material loss in excess of the accrued amount is not probable and estimable and the Company is not able to estimate a possible loss or range of loss at this time.
	Securities and Other Shareholder Litigation
	March 2010 Securities Class Action Litigation: In March 2010, a securities lawsuit seeking class action status was filed in federal district court in Minnesota against the Company and certain officers (collectively, the defendants) on behalf of purchasers of St. Jude Medical common stock between April 22, 2009 and October 6, 2009. The lawsuit relates to the Company's earnings announcements for the first, second and third quarters of 2009, as well as a preliminary earnings release dated October 6, 2009. The complaint, which seeks unspecified damages and other relief as well as attorneys' fees, alleges that the defendants failed to disclose that it was experiencing a slowdown in demand for its products and was not receiving anticipated orders for cardiac rhythm management devices. Class members allege that the defendant's failure to disclose the above information resulted in the class purchasing St. Jude Medical stock at an artificially inflated price. In December 2011, the Court issued a decision denying a motion to dismiss filed by the defendants in October 2010. In October 2012, the Court granted plaintiffs' motion to certify the case as a class action and the discovery phase of the case closed in September 2013. In October 2013, the defendants filed a motion for summary judgment. In November 2014, the defendants filed a motion for leave to proceed with a motion to decertify the class, which the Court denied in December 2014. On February 18, 2015, the parties entered into a written settlement agreement resolving the case, pending notification to class members and subject to court approval. Under the settlement, the Company agreed to make a payment of $50 million to resolve all of the class claims and recorded a charge of that amount during the fourth quarter of 2014. The Company had estimated its damages exposure on the claims alleged to be approximately $475 million. A preliminary order approving the settlement was entered by the District Court on March 9, 2015. The final settlement approval hearing will take place on June 12, 2015. During the first quarter of 2015, the Company received insurance recoveries of $40 million. The Company intends to pursue collection of additional insurance recoveries from one of its insurance carriers.
	December 2012 Securities Litigation: On December 7, 2012, a putative securities class action lawsuit was filed in federal district court in Minnesota against the Company and an officer (collectively, the defendants) for alleged violations of the federal securities laws, on behalf of all purchasers of the publicly traded securities of the defendants between October 17, 2012 and November 20, 2012. The complaint, which sought unspecified damages and other relief as well as attorneys' fees, challenges the Company’s disclosures concerning its high voltage cardiac rhythm lead products during the purported class period. On December 10, 2012, a second putative securities class action lawsuit was filed in federal district court in Minnesota against the Company and certain officers for alleged violations of the federal securities laws, on behalf of all purchasers of the publicly traded securities of the Company between October 19, 2011 and November 20, 2012. The second complaint alleged similar claims and sought similar relief. In March 2013, the Court consolidated the two cases and appointed a lead counsel and lead plaintiff. A consolidated amended complaint was served and filed in June 2013, alleging false or misleading representations made during the class period extending from February 5, 2010 through November 7, 2012. In September 2013, the defendants filed a motion to dismiss the consolidated amended complaint. On March 10, 2014, the Court ruled on the motion to dismiss, denying the motion in part and granting the motion in part. On October 7, 2014, the lead plaintiff filed a second amended complaint. Like the original consolidated amended complaint, the plaintiffs did not assert any specific amount of compensation in the second amended complaint. The plaintiffs filed their motion for class certification on January 15, 2015. The Company will file a response, and a hearing before the Court on the plaintiffs' class certification will be scheduled at some point in the future. The Company intends to continue to vigorously defend against the claims asserted in this matter.
	The Company has not recorded an expense related to any potential damages in connection with the December 2012 Securities Litigation because any potential loss is not probable or reasonably estimable. Because, based on the Company’s historical experience, the amount ultimately paid, if any, often does not bear any relationship to the amount claimed, the Company cannot reasonably estimate a loss or range of loss, if any, that may result from these matters.
	Governmental Investigations
	In March 2010, the Company received a Civil Investigative Demand (CID) from the Civil Division of the Department of Justice (DOJ). The CID requests documents and sets forth interrogatories related to communications by and within the Company on various indications for implantable cardioverter defibrillator (ICD)s and a National Coverage Decision issued by Centers for Medicare and Medicaid Services. Similar requests were made of the Company's major competitors. The Company provided its response to the DOJ in June 2010 and no further activity involving the Company has occurred in this matter since then.
	On September 20, 2012, the Office of Inspector General for the Department of Health and Human Services (OIG) issued a subpoena requiring the Company to produce certain documents related to payments made by the Company to healthcare professionals practicing in California, Florida and Arizona, as well as policies and procedures related to payments made by the Company to non-employee healthcare professionals. The Company provided its response to the OIG in May 2013 and no further activity involving the Company has occurred in this matter since then.
	In April 2014, the Company received a CID from the Civil Division of the DOJ stating that it was investigating the Company for potential False Claims Act violations relating to allegations that certain health care facilities and a physician group may have submitted false claims to federal health care programs as a result of alleged inducements paid by the Company to implant the Company’s cardiac devices. The Company provided its response to the OIG beginning in July 2014 and ending in October 2014. On April 1, 2015, the U.S. District Court for the Southern District of Alabama unsealed a qui tam complaint upon which the CID was based. The unsealed record revealed that the DOJ declined to intervene on February 13, 2015. Thereafter, the qui tam relator moved to dismiss the complaint without prejudice. On April 1, 2015, the Court granted the relator’s motion and dismissed the action.
	As indicated, the Company has cooperated with these investigations and has responded to the requests received. However, the Company cannot predict when the outstanding investigations will be resolved, their outcome or their impact on the Company. Based on the Company’s historical experience, the amount paid, if any, in connection with any governmental investigation typically does not bear any relationship the nature or subject of the investigation, the Company cannot reasonably estimate a loss or range of loss, if any, that may result from these matters. The Company has not recorded an expense related to any potential damages in connection with these governmental matters because any potential loss is not probable or reasonably estimable.
	Product Warranties
	The Company offers a warranty on various products, the most significant of which relate to pacemaker and ICD systems. The Company estimates the costs it expects to incur under its warranties and records a liability for such costs at the time the product is sold. Factors that affect the Company's warranty liability include the number of units sold, historical and anticipated rates of warranty claims and cost per claim. The Company regularly assesses the adequacy of its warranty liabilities and adjusts the amounts as necessary.
	Changes in the Company’s product warranty liability during the three months ended April 4, 2015 and March 29, 2014 were as follows (in millions):
		Three Months Ended
		April 4, 2015			March 29, 2014
	Balance at beginning of period	$	35		$	37
	Warranty expense (income) recognized	(2		)	1
	Warranty credits issued	(1		)	(1		)
	Balance at end of period	$	32		$	37

Special_Charges

Special Charges	3 Months Ended
	Apr. 04, 2015
Special Charges [Abstract]
Special Charges	SPECIAL CHARGES
	The Company recognizes certain transactions and events as special charges in its Condensed Consolidated Financial Statements. These charges (such as restructuring charges, impairment charges, certain legal settlements or product field action costs and litigation costs) result from facts and circumstances that vary in frequency and impact on the Company's results of operations.
	Manufacturing and Supply Chain Optimization Plan
	During 2014, the Company initiated the Manufacturing and Supply Chain Optimization Plan to leverage economies of scale, streamline distribution methods, drive process improvements through global synergies, balance plant utilization levels, centralize certain vendor relationships and reduce overall costs. During 2014, the Company incurred charges of $32 million related to severance and other termination benefits, fixed assets associated with information technology assets no longer expected to be utilized and distributor and other contract termination costs.
	During the first quarter of 2015, the Company incurred additional charges of $8 million primarily related to severance and other termination benefits as well as other contract termination costs associated with the elimination of certain operational, quality and hardware development activities at a research and development facility and continued exit costs related to a facility closure in the United States. The Company currently expects to incur approximately $40 million during the remainder of 2015 to complete the plan, but may incur additional charges in future periods.
	A summary of the activity related to the Manufacturing and Supply Chain Optimization Plan accrual is as follows (in millions):
		Employee			Inventory			Fixed			Other Restructuring Costs			Total
		Termination			Charges			Asset
		Costs						Charges
	Balance at December 28, 2013	$	—		$	—		$	—		$	—		$	—
	Cost of sales special charges	7			—			—			—			7
	Special charges	12			—			5			8			25
	Non-cash charges used	—			—			(5		)	—			(5		)
	Cash payments	(5		)	—			—			(2		)	(7		)
	Balance at January 3, 2015	14			—			—			6			20
	Cost of sales special charges	1			1			—			—			2
	Special charges	3			—			—			3			6
	Non-cash charges used	—			(1		)	—			—			(1		)
	Cash payments	(5		)	—			—			(5		)	(10		)
	Foreign exchange rate impact	—			—			—			(1		)	(1		)
	Balance at April 4, 2015	$	13		$	—		$	—		$	3		$	16
	2012 Business Realignment Plan
	During 2012, the Company realigned its product divisions into two new operating divisions: the Implantable Electronic Systems Division (combining its legacy Cardiac Rhythm Management and Neuromodulation product divisions) and the Cardiovascular and Ablation Technologies Division (combining its legacy Cardiovascular and Atrial Fibrillation product divisions). In addition, the Company centralized certain support functions, including information technology, human resources, legal, business development and certain marketing functions. The organizational changes have been part of a comprehensive plan to accelerate the Company's growth, reduce costs, leverage economies of scale and increase investment in product development.
	During 2014, the Company announced additional organizational changes including the combination of its Implantable Electronic Systems Division and Cardiovascular and Ablation Technologies Division, resulting in an integrated research and development (R&D) organization and a consolidation of manufacturing and supply chain operations worldwide. The integration was conducted in a phased approach during 2014. In connection with these actions, the Company incurred $108 million of special charges associated with the 2012 Business Realignment Plan. These charges primarily included severance and other termination benefits and other restructuring costs, including distributor and other contract termination costs, costs associated with the discontinuation of a clinical trial and planned exit costs related to a facility in Europe. Additionally, the Company recognized inventory and fixed asset write-offs related to a discontinued clinical trial and fixed asset write-offs associated with projects abandoned under the new realigned structure.
	During the first quarter of 2015, the Company incurred additional charges of $5 million primarily related to severance and other termination benefits and other restructuring costs, including contract termination costs, moving expenses and other exit costs predominately associated with the facility closure in Europe. The Company currently expects to incur approximately $4 million during the remainder of 2015 to complete the plan.
	A summary of the activity related to the 2012 Business Realignment Plan accrual is as follows (in millions):
		Employee			Inventory			Fixed			Other			Total
		Termination			Charges			Asset			Restructuring
		Costs						Charges			Costs
	Balance at December 28, 2013	$	54		$	—		$	—		$	33		$	87
	Cost of sales special charges	8			8			13			1			30
	Special charges	36			—			7			35			78
	Non-cash charges used	—			(8		)	(20		)	—			(28		)
	Cash payments	(69		)	—			—			(56		)	(125		)
	Balance at January 3, 2015	26			—			—			12			38
	Cost of sales special charges	1			1			—			—			2
	Special charges	—			—			1			2			3
	Non-cash charges used	—			(1		)	(1		)	—			(2		)
	Cash payments	(6		)	—			—			—			(6		)
	Foreign exchange rate impact	(2		)	—			—			—			(2		)
	Balance at April 4, 2015	$	19		$	—		$	—		$	14		$	33
	2011 Restructuring Plan
	During 2011, the Company incurred special charges to realign certain activities in the Company's legacy Cardiac Rhythm Management business and sales and selling support organizations. The restructuring actions included phasing out Cardiac Rhythm Management manufacturing and R&D operations in a country in Europe, reductions in the Company's workforce and rationalizing product lines. The 2011 Restructuring Plan was completed in 2013 and the remaining accrual balance is not material.
	Other Special Charges
	Legal settlements: In connection with the March 2010 Securities Class Action Litigation, the Company recognized $10 million in insurance recoveries as a special benefit during the first quarter of 2015 (see Note 4).
	Product field action costs and litigation costs: During the first quarter of 2015, the Company recognized $5 million of litigation charges for expected future probable and estimable legal costs associated with outstanding legal matters related to the Company's product field actions. Charges in excess of the amounts accrued are reasonably possible and depend on a number of factors, such as the type of claims received and the cost to defend. Partially offsetting this special charge, the Company recognized a $2 million benefit in cost of sales special charges for salvaged inventory related to certain ICDs that were identified during 2014 as having a potential battery anomaly.

Net_Earnings_Per_Share

Net Earnings Per Share	3 Months Ended
	Apr. 04, 2015
Earnings Per Share [Abstract]
Net Earnings Per Share	NET EARNINGS PER SHARE
	The table below sets forth the computation of basic and diluted net earnings per share attributable to St. Jude Medical, Inc. (in millions, except per share amounts):
		Three Months Ended
		April 4, 2015		March 29, 2014
	Numerator:
	Net earnings attributable to St. Jude Medical, Inc.	$	262	$	249
	Denominator:
	Basic weighted average shares outstanding	283		284.4
	Dilution associated with stock-based compensation plans	4.1		4.9
	Diluted weighted average shares outstanding	287.1		289.3
	Basic net earnings per share attributable to St. Jude Medical, Inc.	$	0.93	$	0.88
	Diluted net earnings per share attributable to St. Jude Medical, Inc.	$	0.91	$	0.86
	Approximately 4.1 million and 2.7 million shares of common stock subject to stock options and restricted stock units were excluded from the diluted net earnings per share computation for the three months ended April 4, 2015 and March 29, 2014, respectively, because they were not dilutive.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income and Supplemental Equity Information	3 Months Ended
	Apr. 04, 2015
Accumulated Comprehensive Income and Supplemental Equity [Abstract]
Accumulated Other Comprehensive Income and Supplemental Equity Information	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) AND SUPPLEMENTAL EQUITY INFORMATION
	The tables below present the changes in each component of accumulated other comprehensive income, net of tax, including other comprehensive income and reclassifications out of accumulated other comprehensive income into net earnings for the three months ended April 4, 2015 and March 29, 2014, respectively (in millions):
		Unrealized
		Gain (Loss) On			Unrealized			Foreign			Accumulated
		Available-for-			Gain (Loss) On			Currency			Other
	For the three months ended	sale			Derivative Instruments			translation adjustment			Comprehensive Income (Loss)
	4-Apr-15	Securities
	Accumulated other comprehensive income (loss) as of January 3, 2015	$	15		$	3		$	(191	)	$	(173	)
	Other comprehensive income (loss) before reclassifications	3			29			(127		)	(95		)
	Amounts reclassified to net earnings from accumulated other comprehensive income	(2		)	—			—			(2		)
	Other comprehensive income (loss)	1			29			(127		)	(97		)
	Accumulated other comprehensive income (loss) as of April 4, 2015	$	16		$	32		$	(318	)	$	(270	)
		Unrealized
		Gain (Loss) On			Unrealized			Foreign			Accumulated
		Available-for-			Gain (Loss) On			Currency			Other
	For the three months ended	sale			Derivative Instruments			translation adjustment			Comprehensive Income (Loss)
	29-Mar-14	Securities
	Accumulated other comprehensive income (loss) as of December 28, 2013	$	17		$	3		$	26		$	46
	Other comprehensive income (loss) before reclassifications	—			—			10			10
	Amounts reclassified to net earnings from accumulated other comprehensive income	—			—			—			—
	Other comprehensive income (loss)	—			—			10			10
	Accumulated other comprehensive income (loss) as of March 29, 2014	$	17		$	3		$	36		$	56
	Income taxes are not provided for foreign translation related to permanent investments in international subsidiaries. Reclassification adjustments are made to avoid double counting items in comprehensive income items that are also recorded as part of net earnings.
	The following table provides details about reclassifications out of accumulated other comprehensive income and the line items impacted in the Company's Condensed Consolidated Statements of Earnings during the three months ended April 4, 2015 and March 29, 2014, respectively (in millions):
		Amount reclassified from accumulated other comprehensive income
		Three Months Ended
	Details about accumulated other	4-Apr-15			29-Mar-14			Statements of Earnings Classification
	comprehensive income components
	Unrealized gain on available-for-sale securities:
	Gain on sale of available-for-sale securities	$	(4	)	$	—		Other (income) expense
	Tax effect	2			—			Income tax expense
	Net of tax	$	(2	)	$	—
	The Company's realized (gains) and losses on its available-for-sales securities are computed using the specific identification method.
	Supplemental Equity Information
	On January 13, 2015, the Company authorized a share repurchase program of up to $500 million of its outstanding common stock. The Company began repurchasing shares on January 30, 2015. From January 30, 2015 through March 2, 2015, the Company repurchased approximately 7.5 million shares for $500 million at an average repurchase price of $66.96 per share.
	The supplemental equity schedules below present changes in the Company's noncontrolling interest for the three months ended April 4, 2015 and March 29, 2014, respectively (in millions):
		Total
		Shareholders'
		Equity
		Before						Total
		Noncontrolling			Noncontrolling			Shareholders'
	For the three months ended April 4, 2015	Interest			Interest			Equity
	Balance at January 3, 2015	$	4,199		$	45		$	4,244
	Net earnings	262			(6		)	256
	Other comprehensive income (loss)	(97		)	—			(97		)
	Cash dividends declared	(81		)	—			(81		)
	Repurchases of common stock	(500		)	—			(500		)
	Stock-based compensation	17			—			17
	Common stock issued under employee stock plans and other, net	38			—			38
	Tax benefit from stock plans	5			—			5
	Balance at April 4, 2015	$	3,843		$	39		$	3,882
		Total
		Shareholders'
		Equity
		Before						Total
		Noncontrolling			Noncontrolling			Shareholders'
	For the three months ended March 29, 2014	Interest			Interest			Equity
	Balance at December 28, 2013	$	4,231		$	173		$	4,404
	Net earnings	249			(10		)	239
	Other comprehensive income (loss)	10			—			10
	Cash dividends declared	(77		)	—			(77		)
	Repurchases of common stock	(434		)	—			(434		)
	Stock-based compensation	17			—			17
	Common stock issued under employee stock plans and other, net	60			—			60
Tax benefit from stock plans	9			—			9
Balance at March 29, 2014	$	4,065		$	163		$	4,228
During the second quarter of 2015, the Company exercised its exclusive option and paid $175 million to Spinal Modulation’s shareholders to obtain the remaining 81% ownership interest in the company that it did not previously own. In accordance with the terms of the original investment agreement, the Company will record estimates for additional payments due upon certain regulatory milestones and achievement of certain revenue targets.

Income_Taxes

Income Taxes	3 Months Ended
	Apr. 04, 2015
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES
	As of April 4, 2015, the Company had $335 million accrued for uncertain tax positions, all of which would affect the Company’s effective tax rate if recognized. Additionally, the Company had $47 million accrued for gross interest and penalties as of April 4, 2015. At January 3, 2015, the liability for uncertain tax positions was $328 million and the accrual for gross interest and penalties was $44 million.
	The Company is subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. The Company has substantially concluded all material U.S. federal, state, foreign and local income tax matters for all tax years through 2004. In April 2015, the U.S. Internal Revenue Service (IRS) completed an audit of the Company’s 2010 and 2011 tax returns and proposed adjustments in an audit report. In February 2014, the IRS completed an audit of the Company’s 2008 and 2009 tax returns and also proposed adjustments in an audit report. The Company has begun and intends to vigorously defend certain of its positions and initiated defense of these adjustments at the IRS appellate level. An unfavorable outcome could have a material negative impact on the Company's effective income tax rate in future periods. The Company does not expect its uncertain tax positions to change significantly over the next 12 months.
	The Company's effective income tax rate was 16.9% and 18.2% for the first quarter of 2015 and 2014, respectively. The Company’s effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. In addition, the effective tax rate can be impacted each period by discrete factors and events. The effective income tax rate decreased during the three months ended April 4, 2015 compared to the prior year period primarily as a result of changes in the mix of income before income taxes between U.S. and foreign countries.

Fair_Value_Measurements_And_Fi

Fair Value Measurements And Financial Instruments	3 Months Ended
	Apr. 04, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements And Financial Instruments	FAIR VALUE MEASUREMENTS
	The fair value measurement accounting standard provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.
	The categories within the valuation hierarchy are described as follows:
	•	Level 1 – Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.
	•	Level 2 – Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
	•	Level 3 – Inputs to the fair value measurement are unobservable inputs or valuation techniques.
	Assets and Liabilities that are Measured at Fair Value on a Recurring Basis
	The fair value measurement standard applies to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). These financial assets and liabilities include money-market securities, trading marketable securities, available-for-sale marketable securities, derivative instruments and contingent consideration liabilities. The Company continues to record these items at fair value on a recurring basis. The Company does not have any material nonfinancial assets or liabilities that are measured at fair value on a recurring basis. A summary of the valuation methodologies used for the respective financial assets and liabilities measured at fair value on a recurring basis is as follows:
	Money-market securities: The Company’s money-market securities include funds that are traded in active markets and are recorded at fair value based upon the quoted market prices. The Company classifies these securities as level 1.
	Available-for-sale securities: The Company’s available-for-sale securities include publicly-traded equity securities that are traded in active markets and are recorded at fair value based upon the closing stock prices. The Company classifies these securities as level 1.
	Trading securities: The Company’s trading securities include publicly-traded mutual funds that are traded in active markets and are recorded at fair value based upon quoted market prices of the net asset values of the funds. The Company classifies these securities as level 1.
	The following table summarizes the components of the balance of the Company’s available-for-sale securities at April 4, 2015 and January 3, 2015 (in millions):
		April 4, 2015				January 3, 2015
	Adjusted cost	$	5			$	6
	Gross unrealized gains	26				24
	Fair value	$	31			$	30
	Derivative instruments: Fair values for the Company’s derivative financial instruments are based on quoted market prices of comparable instruments, if available, or more commonly on standard pricing models that use as their basis readily observable market parameters from industry standard data providers. These models reflect contractual terms of the derivatives, including period to maturity and market-based parameters such as foreign currency exchange rates. They do not contain a high level of subjectivity as the techniques used in the models do not require significant judgment and inputs are readily observable from actively quoted markets. The Company classifies these instruments as level 2 (see Note 10).
	Contingent consideration: The acquisition date fair value is measured based on the consideration expected to be transferred (probability-weighted), discounted back to present value. The discount rate used is determined at the time of measurement in accordance with accepted valuation methods. The Company measures the liability on a recurring basis using Level 3 inputs including projected revenues or cash flows, growth rates, discount rates, probabilities of payment and projected payment dates. Projected revenues are based on the Company's most recent internal operating budgets and long-term strategic plans. Increases or decreases to any of the inputs may result in significantly higher or lower fair value measurements.
	A summary of assets and liabilities measured at fair value on a recurring basis at April 4, 2015 and January 3, 2015 is as follows (in millions):
		Balance Sheet	April 4, 2015				Quoted Prices			Significant		Significant
		Classification					In Active			Other		Unobservable
							Markets			Observable		Inputs
							(Level 1)			Inputs		(Level 3)
										(Level 2)
	Assets
	Money-market securities	Cash and cash equivalents	$	219			$	219		$	—	$	—
	Available-for-sale	Other current assets	31				31			—		—
	securities
	Foreign currency forward	Other current assets	28				—			28		—
	contracts
	Trading securities	Other assets	315				315			—		—
	Foreign currency forward	Other assets	5				—			5		—
	contracts
	Total assets		$	598			$	565		$	33	$	—
	Liabilities
	Contingent consideration	Other liabilities	$	27			$	—		$	—	$	27
	Total liabilities		$	27			$	—		$	—	$	27
		Balance Sheet	January 3, 2015				Quoted Prices			Significant		Significant
		Classification					In Active			Other		Unobservable
							Markets			Observable		Inputs
							(Level 1)			Inputs		(Level 3)
										(Level 2)
	Assets
	Money-market securities	Cash and cash equivalents	$	729			$	729		$	—	$	—
	Available-for-sale securities	Other current assets	30				30			—		—
	Trading securities	Other assets	301				301			—		—
	Total assets		$	1,060			$	1,060		$	—	$	—
	Liabilities
	Contingent consideration	Other liabilities	$	50			$	—		$	—	$	50
	Total liabilities		$	50			$	—		$	—	$	50
	The recurring Level 3 fair value measurements of the Company's contingent consideration liability include the following significant unobservable inputs (in millions):
	Contingent Consideration Liability	Fair Value as of April 4, 2015			Valuation Technique		Unobservable Input		Range
	Nanostim revenue-based milestone	$	27		Probability Weighted Discounted Cash Flow		Discount Rate			5.00%
							Probability of Payment			90%
							Projected Years of Three Annual Payments		2016, 2017, 2018
	Total contingent consideration liability	$	27
	Additionally, the following table provides a reconciliation of the beginning and ending balances of the Company' contingent consideration liability associated with its Nanostim acquisition since January 3, 2015 as of April 4, 2015 (in millions):
		Nanostim
	Balance as of January 3, 2015	$	50
	Change in fair value of contingent consideration	(23		)
	Balance as of April 4, 2015	$	27
	Assets and Liabilities that are Measured at Fair Value on a Nonrecurring Basis
	Disclosures are required for certain assets and liabilities that are measured at fair value but are recognized and disclosed at fair value on a nonrecurring basis in periods subsequent to initial recognition. For St. Jude Medical, such measurements of fair value primarily relate to long-lived assets, goodwill, indefinite-lived intangible assets and cost method investments.
	Other than the long-lived asset impairment discussed as follows, there were no other material impairments that were measured at fair value on a nonrecurring basis for the three months ended April 4, 2015.
Long-lived assets: During the first quarter of both 2015 and 2014, the Company recognized $1 million of fixed asset write-offs associated with projects abandoned under the new realigned structure. Typically the Company measures the fair value of its long-lived assets, such as its definite-lived intangible assets and property, plant and equipment using independent appraisals, market models and discounted cash flow models. However, as the fixed assets had no alternative future use and therefore no discrete future cash flows, the assets were fully impaired.
Cost method investments: The Company also holds investments in equity securities that are accounted for as cost method investments, which are classified as other assets and measured at fair value on a nonrecurring basis. The carrying value of these investments was $72 million and $71 million as of April 4, 2015 and January 3, 2015, respectively. The fair value of the Company’s cost method investments was not estimated during the first quarter of 2015 since there were no identified events or changes in circumstances that may have had a significant adverse effect on the fair value of these investments.
Fair Value Measurements of Other Financial Instruments
The aggregate fair value of the Company’s fixed-rate senior notes at April 4, 2015 (measured using quoted prices in active markets) was $2,386 million compared to the aggregate carrying value of $2,271 million (inclusive of the terminated interest rate swaps and unamortized debt discounts). The fair value of the Company’s variable-rate debt obligations at April 4, 2015 approximated its aggregate $1,233 million carrying value due to the variable interest rate and short-term nature of these instruments. The Company also had $476 million and $713 million of cash equivalents invested in short-term deposits and interest and non-interest bearing bank accounts at April 4, 2015 and January 3, 2015, respectively.

Derivative_Financial_Instrumen

Derivative Financial Instruments

3 Months Ended

Apr. 04, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

DERIVATIVE FINANCIAL INSTRUMENTS

As a matter of policy, the Company uses derivatives for risk management purposes and it does not use derivatives for trading or speculative purposes. A key risk management objective is to mitigate foreign exchange rate volatility and the associated impact on earnings. The Company's primary way of meeting this objective is for certain of its subsidiaries to enter into derivative contracts with the same critical terms as those subsidiaries’ forecasted amounts of foreign currency costs.

Cash Flow Hedges

In the first quarter of 2015, the Company began to enter into foreign exchange forward contracts to hedge against the effect of exchange rate fluctuations on cash flows denominated in foreign currencies. These transactions are designated as cash flow hedges. The settlement or extension of these derivatives will result in reclassifications from accumulated other comprehensive income to earnings in the period during which the hedged transactions affect earnings and in the same financial statement line item with the earnings effects of the hedged transaction. The Company may dedesignate these cash flow hedge relationships in advance of the occurrence of the forecasted transaction. The portion of gains or losses on the derivative instrument previously accumulated in other comprehensive income for dedesignated hedges remains in accumulated other comprehensive income until the forecasted transaction occurs. Changes in the value of derivative instruments after dedesignation, but before settlement of the forward contract, are recorded in earnings and are included in the Derivatives Not Designated as Hedging Instruments section below. Hedge ineffectiveness and the amount excluded from effectiveness testing recognized in earnings on cash flow hedges were not material for the three months ended April 4, 2015. The Company hedges its exposure to the variability in future cash flows of forecasted transactions for periods of up to 24 months. The dollar equivalent gross notional amount of the Company’s foreign exchange forward contracts designated as cash flow hedges at April 4, 2015 was approximately $1.1 billion.

As of April 4, 2015, the Company had a balance of $29 million associated with the after-tax net unrealized gain related to foreign currency forward contracts recorded in accumulated other comprehensive income. Based on exchange rates as of April 4, 2015, the Company expects to reclassify approximately $22 million (after-tax) to earnings over the next 12 months contemporaneously with the earnings effects of the related forecasted transactions (with the impact offset by cash flows from the underlying hedged items).

The following table provides the (gains) losses related to derivative instruments designated as cash flow hedges, including the location in the Condensed Consolidated Statements of Earnings and the Condensed Consolidated Statements of Comprehensive Income (in millions):

Pre-tax (Gain) Loss

Recognized in

Pre-tax (Gain) Loss Recognized

Other

in Earnings on Effective Portion

Ineffective Portion of (Gain) Loss

Comprehensive

of Derivative as a Result of

on Derivative and Amount

Three

Income on Effective

Reclassification from

Excluded from Effectiveness

months

Portion of

Accumulated Other

Testing Recognized

ended

Derivative

Comprehensive Income

in Earnings

4-Apr-15

Amount

Amount

Location

Amount

Location

Derivatives in Cash Flow Hedging Relationships

Foreign currency forward contracts

$

(34

)

$

—

Cost of sales

$

—

Cost of sales

Reclassifications from accumulated other comprehensive income into earnings include accumulated (gains) losses on dedesignated hedges at the time earnings are impacted.

Derivatives Not Designated as Hedging Instruments

Derivatives not designated as hedging instruments include dedesignated foreign currency forward contracts that formerly were designated in cash flow hedging relationships (as referenced in the Cash Flow Hedges section above). In addition, the Company enters into foreign currency forward contracts to economically hedge the foreign currency impact of assets and liabilities (including intercompany assets and liabilities) denominated in nonfunctional currencies. These derivative instruments are not designated in hedging relationships; therefore, fair value gains and losses on these contracts are recorded in earnings. The dollar equivalent gross notional amount of these forward contracts not designated as hedging instruments totaled $190 million as of April 4, 2015. The fair value of the Company's outstanding contracts was immaterial as of April 4, 2015 and January 3, 2015.

The following table provides the (gains) losses related to derivative instruments not designated as hedging instruments, including the location in the Condensed Consolidated Statements of Earnings (in millions):

Three months ended April 4, 2015

(Gain) Loss on Derivatives

Recognized in Earnings

Derivatives Not Designated as Hedging Instruments

Amount

Location

Foreign currency forward contracts

$

(9

)

Other (income) expense

The net (gains) losses were almost entirely offset by corresponding net (losses) gains on the foreign currency exposures being managed.

Location and Fair Value Amount of Derivative Instruments

The following table summarizes the fair value of the Company’s derivative instruments and their locations in the Condensed Consolidated Balance Sheets as of April 4, 2015 (in millions):

Assets

Fair Value of Derivative Instruments

Amount

Location

Derivatives Designated as Hedging Instruments

Foreign currency forward contracts

$

24

Other current assets

Foreign currency forward contracts

5

Other assets

Derivatives Not Designated as Hedging Instruments

Foreign currency forward contracts

4

Other current assets

Total

$

33

Additional information with respect to the fair values of derivative instruments is included in Note 9.

Credit Risk and Offsetting of Assets and Liabilities of Derivative Instruments

Fair values of the Company's derivatives can change significantly from period to period based on, among other factors, market movements and changes in the Company's positions. However, the Company’s risk is limited to the fair value of the instruments. The Company monitors its exposure to counterparty credit risk (the risk that counterparties will default and not make payments to the Company according to the terms of the agreements) by selecting major international banks and financial institutions as counterparties and by entering into master netting arrangements with counterparties when possible. A master netting arrangement may allow each counterparty to net settle amounts owed between a St. Jude Medical entity and the counterparty as a result of multiple, separate derivative transactions. As of April 4, 2015, St. Jude Medical had International Swaps and Derivatives Association agreements with three applicable banks and financial institutions that contain netting provisions.

The Company has elected to present the fair values of derivative assets and liabilities within the Company’s Condensed Consolidated Balance Sheets on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. However, the following table provides information as though the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria in the event of default or termination as stipulated by the terms of the netting arrangements with each of the counterparties as of April 4, 2015 (in millions):

Gross Amounts not Offset in the Condensed Consolidated Balance Sheet that are Subject to Master Netting Agreements

Gross Amount of

Eligible Offsetting

Gross Amount of

Recognized

Derivative Assets

Derivative Liabilities

Net

Presented in the

Presented in the

Cash

Amount of

Condensed Consolidated

Condensed Consolidated

Collateral

Derivative

Derivatives as of April 4, 2015

Balance Sheet

Balance Sheet

Received

Assets

Derivatives subject to master netting agreements

$

9

$

—

$

—

$

9

Derivatives not subject to master netting agreements

24

24

Total

$

33

$

—

$

—

$

33

For each counterparty, if netted, the Company would offset the asset and liability balances of all derivatives at the end of the reporting period. Derivatives not subject to master netting agreements are not eligible for net presentation. As of April 4, 2015, no cash collateral had been received or pledged related to these derivative instruments.

Business_Combinations_and_Vari1

Business Combinations and Variable Interest Entities (Tables) (Spinal Modulation [Member])	3 Months Ended
	Apr. 04, 2015
Spinal Modulation [Member]
Schedule of Variable Interest Entities [Table Text Block]	The following table summarizes Spinal Modulation’s assets and liabilities included in St. Jude Medical Inc.'s consolidated balance sheet as of April 4, 2015 after elimination of all intercompany balances and transactions (in millions):
		4-Apr-15
	Cash and cash equivalents	$	9
	Other current assets	7
	Goodwill	46
	In-process research and development (IPR&D)	45
	Other intangible assets	7
	Total assets	$	114
	Current liabilities	$	7
	Deferred income taxes	19
	Total liabilities	$	26
	Non-controlling interest	$	39

Debt_Tables

Debt (Tables)	3 Months Ended
	Apr. 04, 2015
Debt Disclosure [Abstract]
Schedule Of Long-Term Debt	The carrying value of the Company’s debt, including discounts, the fair value of an interest rate swap agreement and the remaining deferred gain from a terminated interest rate swap agreement, consisted of the following (in millions):
		April 4, 2015			January 3, 2015
	Term loan due June 2015	$	—		$	500
	Term loan due August 2015	—			250
	2.50% senior notes due 2016	504			506
	3.25% senior notes due 2023	897			896
	4.75% senior notes due 2043	696			696
	1.58% Yen-denominated senior notes due 2017	68			68
	2.04% Yen-denominated senior notes due 2020	106			107
	Yen-denominated credit facilities	54			54
	Commercial paper borrowings	1,179			789
	Total debt	3,504			3,866
	Less: current debt obligations	1,737			1,593
	Long-term debt	$	1,767		$	2,273
Schedule of Maturities of Long-term Debt	Contractual maturities of the Company's debt for the next five fiscal years and thereafter, excluding discounts, the fair value of an interest rate swap agreement and the remaining deferred gain from a terminated interest rate swap agreement, as of April 4, 2015 are as follows (in million):
		Remainder of 2015		2016			2017		2018		2019		After 2019
	Expected future minimum principal payments	$	1,206	$	527		$	68	$	—	$	—	$	1,707

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	3 Months Ended
	Apr. 04, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule Of Product Warranty Liability	Changes in the Company’s product warranty liability during the three months ended April 4, 2015 and March 29, 2014 were as follows (in millions):
		Three Months Ended
		April 4, 2015			March 29, 2014
	Balance at beginning of period	$	35		$	37
	Warranty expense (income) recognized	(2		)	1
	Warranty credits issued	(1		)	(1		)
	Balance at end of period	$	32		$	37

Special_Charges_Tables

Special Charges (Tables)	3 Months Ended
	Apr. 04, 2015
Manufacturing and Supply Chain Optimization Plan
Restructuring Cost and Reserve
Summary Of Activity Related To Special Charge Restructuring Accrual	A summary of the activity related to the Manufacturing and Supply Chain Optimization Plan accrual is as follows (in millions):
		Employee			Inventory			Fixed			Other Restructuring Costs			Total
		Termination			Charges			Asset
		Costs						Charges
	Balance at December 28, 2013	$	—		$	—		$	—		$	—		$	—
	Cost of sales special charges	7			—			—			—			7
	Special charges	12			—			5			8			25
	Non-cash charges used	—			—			(5		)	—			(5		)
	Cash payments	(5		)	—			—			(2		)	(7		)
	Balance at January 3, 2015	14			—			—			6			20
	Cost of sales special charges	1			1			—			—			2
	Special charges	3			—			—			3			6
	Non-cash charges used	—			(1		)	—			—			(1		)
	Cash payments	(5		)	—			—			(5		)	(10		)
	Foreign exchange rate impact	—			—			—			(1		)	(1		)
	Balance at April 4, 2015	$	13		$	—		$	—		$	3		$	16
2012 Business Realignment Restructuring Plan
Restructuring Cost and Reserve
Summary Of Activity Related To Special Charge Restructuring Accrual	A summary of the activity related to the 2012 Business Realignment Plan accrual is as follows (in millions):
		Employee			Inventory			Fixed			Other			Total
		Termination			Charges			Asset			Restructuring
		Costs						Charges			Costs
	Balance at December 28, 2013	$	54		$	—		$	—		$	33		$	87
	Cost of sales special charges	8			8			13			1			30
	Special charges	36			—			7			35			78
	Non-cash charges used	—			(8		)	(20		)	—			(28		)
	Cash payments	(69		)	—			—			(56		)	(125		)
	Balance at January 3, 2015	26			—			—			12			38
	Cost of sales special charges	1			1			—			—			2
	Special charges	—			—			1			2			3
	Non-cash charges used	—			(1		)	(1		)	—			(2		)
	Cash payments	(6		)	—			—			—			(6		)
	Foreign exchange rate impact	(2		)	—			—			—			(2		)
	Balance at April 4, 2015	$	19		$	—		$	—		$	14		$	33

Net_Earnings_Per_Share_Tables

Net Earnings Per Share (Tables)	3 Months Ended
	Apr. 04, 2015
Earnings Per Share [Abstract]
Schedule Of Computation Of Basic And Diluted Net Earnings Per Share	The table below sets forth the computation of basic and diluted net earnings per share attributable to St. Jude Medical, Inc. (in millions, except per share amounts):
		Three Months Ended
		April 4, 2015		March 29, 2014
	Numerator:
	Net earnings attributable to St. Jude Medical, Inc.	$	262	$	249
	Denominator:
	Basic weighted average shares outstanding	283		284.4
	Dilution associated with stock-based compensation plans	4.1		4.9
	Diluted weighted average shares outstanding	287.1		289.3
	Basic net earnings per share attributable to St. Jude Medical, Inc.	$	0.93	$	0.88
	Diluted net earnings per share attributable to St. Jude Medical, Inc.	$	0.91	$	0.86

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income and Supplemental Equity Information (Tables)	3 Months Ended
	Apr. 04, 2015
Accumulated Comprehensive Income and Supplemental Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The tables below present the changes in each component of accumulated other comprehensive income, net of tax, including other comprehensive income and reclassifications out of accumulated other comprehensive income into net earnings for the three months ended April 4, 2015 and March 29, 2014, respectively (in millions):
		Unrealized
		Gain (Loss) On			Unrealized			Foreign			Accumulated
		Available-for-			Gain (Loss) On			Currency			Other
	For the three months ended	sale			Derivative Instruments			translation adjustment			Comprehensive Income (Loss)
	4-Apr-15	Securities
	Accumulated other comprehensive income (loss) as of January 3, 2015	$	15		$	3		$	(191	)	$	(173	)
	Other comprehensive income (loss) before reclassifications	3			29			(127		)	(95		)
	Amounts reclassified to net earnings from accumulated other comprehensive income	(2		)	—			—			(2		)
	Other comprehensive income (loss)	1			29			(127		)	(97		)
	Accumulated other comprehensive income (loss) as of April 4, 2015	$	16		$	32		$	(318	)	$	(270	)
		Unrealized
		Gain (Loss) On			Unrealized			Foreign			Accumulated
		Available-for-			Gain (Loss) On			Currency			Other
	For the three months ended	sale			Derivative Instruments			translation adjustment			Comprehensive Income (Loss)
	29-Mar-14	Securities
	Accumulated other comprehensive income (loss) as of December 28, 2013	$	17		$	3		$	26		$	46
	Other comprehensive income (loss) before reclassifications	—			—			10			10
	Amounts reclassified to net earnings from accumulated other comprehensive income	—			—			—			—
	Other comprehensive income (loss)	—			—			10			10
	Accumulated other comprehensive income (loss) as of March 29, 2014	$	17		$	3		$	36		$	56
Reclassification out of Accumulated Other Comprehensive Income	The following table provides details about reclassifications out of accumulated other comprehensive income and the line items impacted in the Company's Condensed Consolidated Statements of Earnings during the three months ended April 4, 2015 and March 29, 2014, respectively (in millions):
		Amount reclassified from accumulated other comprehensive income
		Three Months Ended
	Details about accumulated other	4-Apr-15			29-Mar-14			Statements of Earnings Classification
	comprehensive income components
	Unrealized gain on available-for-sale securities:
	Gain on sale of available-for-sale securities	$	(4	)	$	—		Other (income) expense
	Tax effect	2			—			Income tax expense
	Net of tax	$	(2	)	$	—
Stockholders' Equity Note Disclosure	The supplemental equity schedules below present changes in the Company's noncontrolling interest for the three months ended April 4, 2015 and March 29, 2014, respectively (in millions):
		Total
		Shareholders'
		Equity
		Before						Total
		Noncontrolling			Noncontrolling			Shareholders'
	For the three months ended April 4, 2015	Interest			Interest			Equity
	Balance at January 3, 2015	$	4,199		$	45		$	4,244
	Net earnings	262			(6		)	256
	Other comprehensive income (loss)	(97		)	—			(97		)
	Cash dividends declared	(81		)	—			(81		)
	Repurchases of common stock	(500		)	—			(500		)
	Stock-based compensation	17			—			17
	Common stock issued under employee stock plans and other, net	38			—			38
	Tax benefit from stock plans	5			—			5
	Balance at April 4, 2015	$	3,843		$	39		$	3,882
		Total
		Shareholders'
		Equity
		Before						Total
		Noncontrolling			Noncontrolling			Shareholders'
	For the three months ended March 29, 2014	Interest			Interest			Equity
	Balance at December 28, 2013	$	4,231		$	173		$	4,404
	Net earnings	249			(10		)	239
	Other comprehensive income (loss)	10			—			10
	Cash dividends declared	(77		)	—			(77		)
	Repurchases of common stock	(434		)	—			(434		)
	Stock-based compensation	17			—			17
	Common stock issued under employee stock plans and other, net	60			—			60
	Tax benefit from stock plans	9			—			9
	Balance at March 29, 2014	$	4,065		$	163		$	4,228
	During the second quarter of 2015, the Company exercised its exclusive option and paid $175 million to Spinal Modulation’s shareholders to obtain the remaining 81% ownership interest in the company that it did not previously own. In accordance with the terms of the original investment agreement, the Company will record estimates for additional payments due upon certain regulatory milestones and achievement of certain revenue targets.

Fair_Value_Measurements_And_Fi1

Fair Value Measurements And Financial Instruments (Tables)	3 Months Ended
	Apr. 04, 2015
Fair Value Disclosures [Abstract]
Summary Of Components Of Available-For-Sale Securities	The following table summarizes the components of the balance of the Company’s available-for-sale securities at April 4, 2015 and January 3, 2015 (in millions):
		April 4, 2015				January 3, 2015
	Adjusted cost	$	5			$	6
	Gross unrealized gains	26				24
	Fair value	$	31			$	30
Summary Of Financial Assets and Liabilities Measured At Fair Value On A Recurring Basis	A summary of assets and liabilities measured at fair value on a recurring basis at April 4, 2015 and January 3, 2015 is as follows (in millions):
		Balance Sheet	April 4, 2015				Quoted Prices			Significant		Significant
		Classification					In Active			Other		Unobservable
							Markets			Observable		Inputs
							(Level 1)			Inputs		(Level 3)
										(Level 2)
	Assets
	Money-market securities	Cash and cash equivalents	$	219			$	219		$	—	$	—
	Available-for-sale	Other current assets	31				31			—		—
	securities
	Foreign currency forward	Other current assets	28				—			28		—
	contracts
	Trading securities	Other assets	315				315			—		—
	Foreign currency forward	Other assets	5				—			5		—
	contracts
	Total assets		$	598			$	565		$	33	$	—
	Liabilities
	Contingent consideration	Other liabilities	$	27			$	—		$	—	$	27
	Total liabilities		$	27			$	—		$	—	$	27
		Balance Sheet	January 3, 2015				Quoted Prices			Significant		Significant
		Classification					In Active			Other		Unobservable
							Markets			Observable		Inputs
							(Level 1)			Inputs		(Level 3)
										(Level 2)
	Assets
	Money-market securities	Cash and cash equivalents	$	729			$	729		$	—	$	—
	Available-for-sale securities	Other current assets	30				30			—		—
	Trading securities	Other assets	301				301			—		—
	Total assets		$	1,060			$	1,060		$	—	$	—
	Liabilities
	Contingent consideration	Other liabilities	$	50			$	—		$	—	$	50
	Total liabilities		$	50			$	—		$	—	$	50
Summary of Level 3 Fair Value Measurements of Contingent Consideration Liability	The recurring Level 3 fair value measurements of the Company's contingent consideration liability include the following significant unobservable inputs (in millions):
	Contingent Consideration Liability	Fair Value as of April 4, 2015			Valuation Technique		Unobservable Input		Range
	Nanostim revenue-based milestone	$	27		Probability Weighted Discounted Cash Flow		Discount Rate			5.00%
							Probability of Payment			90%
							Projected Years of Three Annual Payments		2016, 2017, 2018
	Total contingent consideration liability	$	27
Unobservable Input Reconciliation of Contingent Consideration Liability	Additionally, the following table provides a reconciliation of the beginning and ending balances of the Company' contingent consideration liability associated with its Nanostim acquisition since January 3, 2015 as of April 4, 2015 (in millions):
		Nanostim
	Balance as of January 3, 2015	$	50
	Change in fair value of contingent consideration	(23		)
	Balance as of April 4, 2015	$	27

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Tables)

3 Months Ended

Apr. 04, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Summary of Derivative Instruments (Gain) Loss

The following table provides the (gains) losses related to derivative instruments designated as cash flow hedges, including the location in the Condensed Consolidated Statements of Earnings and the Condensed Consolidated Statements of Comprehensive Income (in millions):

Pre-tax (Gain) Loss

Recognized in

Pre-tax (Gain) Loss Recognized

Other

in Earnings on Effective Portion

Ineffective Portion of (Gain) Loss

Comprehensive

of Derivative as a Result of

on Derivative and Amount

Three

Income on Effective

Reclassification from

Excluded from Effectiveness

months

Portion of

Accumulated Other

Testing Recognized

ended

Derivative

Comprehensive Income

in Earnings

4-Apr-15

Amount

Amount

Location

Amount

Location

Derivatives in Cash Flow Hedging Relationships

Foreign currency forward contracts

$

(34

)

$

—

Cost of sales

$

—

Cost of sales

The following table provides the (gains) losses related to derivative instruments not designated as hedging instruments, including the location in the Condensed Consolidated Statements of Earnings (in millions):

Three months ended April 4, 2015

(Gain) Loss on Derivatives

Recognized in Earnings

Derivatives Not Designated as Hedging Instruments

Amount

Location

Foreign currency forward contracts

$

(9

)

Other (income) expense

Schedule of Fair Value of Derivative Instruments in Statement of Financial Position

The following table summarizes the fair value of the Company’s derivative instruments and their locations in the Condensed Consolidated Balance Sheets as of April 4, 2015 (in millions):

Assets

Fair Value of Derivative Instruments

Amount

Location

Derivatives Designated as Hedging Instruments

Foreign currency forward contracts

$

24

Other current assets

Foreign currency forward contracts

5

Other assets

Derivatives Not Designated as Hedging Instruments

Foreign currency forward contracts

4

Other current assets

Total

$

33

Schedule of Offsetting Derivative Assets

However, the following table provides information as though the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria in the event of default or termination as stipulated by the terms of the netting arrangements with each of the counterparties as of April 4, 2015 (in millions):

Gross Amounts not Offset in the Condensed Consolidated Balance Sheet that are Subject to Master Netting Agreements

Gross Amount of

Eligible Offsetting

Gross Amount of

Recognized

Derivative Assets

Derivative Liabilities

Net

Presented in the

Presented in the

Cash

Amount of

Condensed Consolidated

Condensed Consolidated

Collateral

Derivative

Derivatives as of April 4, 2015

Balance Sheet

Balance Sheet

Received

Assets

Derivatives subject to master netting agreements

$

9

$

—

$

—

$

9

Derivatives not subject to master netting agreements

24

24

Total

$

33

$

—

$

—

$

33

Business_Combinations_and_Vari2

Business Combinations and Variable Interest Entities - Schedule of Variable Interest Entities (Details) (USD $)	Apr. 04, 2015	Jan. 03, 2015
In Millions, unless otherwise specified
Variable Interest Entity [Line Items]
Goodwill	$3,509	$3,532
Spinal Modulation [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	9
Other current assets	7
Goodwill	46
In-process research and development (IPR&D)	45
Other intangible assets	7
Total assets	114
Current liabilities	7
Deferred income taxes	19
Total liabilities	26
Non-controlling interest	$39

Business_Combinations_and_Vari3

Business Combinations and Variable Interest Entities (Details) (Spinal Modulation [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Jun. 29, 2013	Jun. 07, 2013
Equity Security Ownership Interest And Allocated Value For Purchase Option			$40
Noncontrolling Interest, Ownership Percentage by Parent			19.00%
Additional Payment For Acquisition At Company Option			300
Variable Interest Entity, Financial or Other Support, Amount	20
Maximum [Member]
Variable Interest Entity, Financial or Other Support, Amount	25
Revolving Credit Facility [Member]
Variable Interest Entity, Financial or Other Support, Amount		$15

Debt_Schedule_Of_LongTerm_Debt

Debt - Schedule Of Long-Term Debt (Details) (USD $)	Apr. 04, 2015	Jan. 03, 2015
In Millions, unless otherwise specified
Debt Instrument
Total debt	$3,504	$3,866
Less: current debt obligations	1,737	1,593
Long-term debt	1,767	2,273
Term loan due June 2015 | Loans Payable
Debt Instrument
Total debt	0	500
Term loan due August 2015 | Loans Payable
Debt Instrument
Total debt	0	250
2.50% senior notes due 2016 | Senior Notes
Debt Instrument
Total debt	504	506
Debt Instrument, Interest Rate, Stated Percentage	2.50%
3.25% senior notes due 2023 | Senior Notes
Debt Instrument
Total debt	897	896
Debt Instrument, Interest Rate, Stated Percentage	3.25%
4.75% senior notes due 2043 | Senior Notes
Debt Instrument
Total debt	696	696
Debt Instrument, Interest Rate, Stated Percentage	4.75%
1.58% Yen-denominated senior notes due 2017 | Senior Notes
Debt Instrument
Total debt	68	68
Debt Instrument, Interest Rate, Stated Percentage	1.58%
2.04% Yen-denominated senior notes due 2020 | Senior Notes
Debt Instrument
Total debt	106	107
Debt Instrument, Interest Rate, Stated Percentage	2.04%
Yen-denominated credit facilities | Line of Credit
Debt Instrument
Total debt	54	54
Commercial paper borrowings | Commercial Paper
Debt Instrument
Total debt	$1,179	$789

Debt_Schedule_of_Maturities_of

Debt - Schedule of Maturities of Long-term Debt (Details) (USD $)	Apr. 04, 2015
In Millions, unless otherwise specified
Debt Disclosure [Abstract]
Remainder of 2015	$1,206
2016	527
2017	68
2018	0
2019	0
After 2019	$1,707

Debt_Details

Debt (Details)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Apr. 04, 2015	Apr. 04, 2015	Apr. 04, 2015	Apr. 04, 2015	Apr. 04, 2015	Apr. 04, 2015
	Loans Payable	Loans Payable	Loans Payable	Line of Credit	Line of Credit	Japan, Yen	London Interbank Offered Rate (LIBOR) [Member]
	Term loan due June 2015	Term loan due August 2015	Term loan due April 2016 [Member]	Yen-denominated credit facilities	Yen-denominated credit facilities	Line of Credit	Loans Payable
	USD ($)	USD ($)	USD ($)	USD ($)	JPY (¥)		Term loan due April 2016 [Member]
Debt Instrument
Debt instrument term, years	2 years	364 days	364 days
Debt Instrument, Face Amount	$500	$250	$175
Long-term Line of Credit				$27	¥ 3,250
Debt Instrument, Description of Variable Rate Basis						Yen LIBOR	LIBOR
Debt Instrument, Basis Spread on Variable Rate			0.90%	0.25%	0.25%

Commitments_And_Contingencies_1

Commitments And Contingencies - Schedule Of Product Warranty Liability (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014
Commitments and Contingencies Disclosure [Abstract]
Balance at beginning of period	$35	$37
Warranty expense (income) recognized	-2	1
Warranty credits issued	-1	-1
Balance at end of period	$32	$37

Commitments_And_Contingencies_2

Commitments And Contingencies (Details) (USD $)	3 Months Ended		12 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Jan. 03, 2015	Jan. 03, 2015	Mar. 30, 2013	Dec. 17, 2014	1-May-15
March 2010 Securities Class Action
Commitments And Contingencies
Litigation Settlement, Expense		$50
Minimum damage loss claimed			475
Proceeds from Insurance Settlement, Operating Activities	40
December 2012 Securities Litigation
Commitments And Contingencies
Number of cases consolidated				2
Riata Litigation
Commitments And Contingencies
Litigation Settlement, Expense		$15
Loss Contingency, Claims Settled, Number		950
Number of resolved multi-plaintiff lawsuits, excluding class action lawsuits		8	8
Riata Litigation | Minimum
Commitments And Contingencies
Number of lawsuits outstanding					70
Riata Litigation | Subsequent Event
Commitments And Contingencies
Number of lawsuits outstanding						4
Riata Litigation | State and Federal Courts of California
Commitments And Contingencies
Number of claimants in lawsuit		173	173

Special_Charges_Summary_Of_Act

Special Charges - Summary Of Activity Related To Special Charge Restructuring Accrual (Details) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014	Jan. 03, 2015
Manufacturing and Supply Chain Optimization Plan
Restructuring Cost and Reserve
Balance at beginning	$20	$0	$0
Special charges	8		32
Non-cash charges used	-1		-5
Cash payments	-10		-7
Restructuring Reserve, Translation Adjustment	-1
Balance at ending	16		20
Manufacturing and Supply Chain Optimization Plan | Employee Termination Costs
Restructuring Cost and Reserve
Balance at beginning	14	0	0
Non-cash charges used	0		0
Cash payments	-5		-5
Restructuring Reserve, Translation Adjustment	0
Balance at ending	13		14
Manufacturing and Supply Chain Optimization Plan | Inventory Valuation Reserve
Restructuring Cost and Reserve
Balance at beginning	0	0	0
Non-cash charges used	-1		0
Cash payments	0		0
Restructuring Reserve, Translation Adjustment	0
Balance at ending	0		0
Manufacturing and Supply Chain Optimization Plan | Fixed Asset Write-offs
Restructuring Cost and Reserve
Balance at beginning	0	0	0
Non-cash charges used	0		-5
Cash payments	0		0
Restructuring Reserve, Translation Adjustment	0
Balance at ending	0		0
Manufacturing and Supply Chain Optimization Plan | Other Restructuring
Restructuring Cost and Reserve
Balance at beginning	6	0	0
Non-cash charges used	0		0
Cash payments	-5		-2
Restructuring Reserve, Translation Adjustment	-1
Balance at ending	3		6
Manufacturing and Supply Chain Optimization Plan | Cost of Sales
Restructuring Cost and Reserve
Special charges	2		7
Manufacturing and Supply Chain Optimization Plan | Cost of Sales | Employee Termination Costs
Restructuring Cost and Reserve
Special charges, severance and benefit costs	1		7
Manufacturing and Supply Chain Optimization Plan | Cost of Sales | Inventory Valuation Reserve
Restructuring Cost and Reserve
Special charges, inventory obsolescence charges	1		0
Manufacturing and Supply Chain Optimization Plan | Cost of Sales | Fixed Asset Write-offs
Restructuring Cost and Reserve
Special charges, fixed asset impairment charges	0		0
Manufacturing and Supply Chain Optimization Plan | Cost of Sales | Other Restructuring
Restructuring Cost and Reserve
Restructuring reserve period expense	0		0
Manufacturing and Supply Chain Optimization Plan | Operating Expense
Restructuring Cost and Reserve
Special charges	6		25
Manufacturing and Supply Chain Optimization Plan | Operating Expense | Employee Termination Costs
Restructuring Cost and Reserve
Special charges, severance and benefit costs	3		12
Manufacturing and Supply Chain Optimization Plan | Operating Expense | Inventory Valuation Reserve
Restructuring Cost and Reserve
Special charges, inventory obsolescence charges	0		0
Manufacturing and Supply Chain Optimization Plan | Operating Expense | Fixed Asset Write-offs
Restructuring Cost and Reserve
Special charges, fixed asset impairment charges	0		5
Manufacturing and Supply Chain Optimization Plan | Operating Expense | Other Restructuring
Restructuring Cost and Reserve
Restructuring reserve period expense	3		8
2012 Business Realignment Restructuring Plan
Restructuring Cost and Reserve
Balance at beginning	38	87	87
Special charges	5		108
Non-cash charges used	-2		-28
Cash payments	-6		-125
Restructuring Reserve, Translation Adjustment	-2
Balance at ending	33		38
2012 Business Realignment Restructuring Plan | Employee Termination Costs
Restructuring Cost and Reserve
Balance at beginning	26	54	54
Non-cash charges used	0		0
Cash payments	-6		-69
Restructuring Reserve, Translation Adjustment	-2
Balance at ending	19		26
2012 Business Realignment Restructuring Plan | Inventory Valuation Reserve
Restructuring Cost and Reserve
Balance at beginning	0	0	0
Non-cash charges used	-1		-8
Cash payments	0		0
Restructuring Reserve, Translation Adjustment	0
Balance at ending	0		0
2012 Business Realignment Restructuring Plan | Fixed Asset Write-offs
Restructuring Cost and Reserve
Balance at beginning	0	0	0
Special charges, fixed asset impairment charges	1	1
Non-cash charges used	-1		-20
Cash payments	0		0
Restructuring Reserve, Translation Adjustment	0
Balance at ending	0		0
2012 Business Realignment Restructuring Plan | Other Restructuring
Restructuring Cost and Reserve
Balance at beginning	12	33	33
Non-cash charges used	0		0
Cash payments	0		-56
Restructuring Reserve, Translation Adjustment	0
Balance at ending	14		12
2012 Business Realignment Restructuring Plan | Cost of Sales
Restructuring Cost and Reserve
Special charges	2		30
2012 Business Realignment Restructuring Plan | Cost of Sales | Employee Termination Costs
Restructuring Cost and Reserve
Special charges, severance and benefit costs	1		8
2012 Business Realignment Restructuring Plan | Cost of Sales | Inventory Valuation Reserve
Restructuring Cost and Reserve
Special charges, inventory obsolescence charges	1		8
2012 Business Realignment Restructuring Plan | Cost of Sales | Fixed Asset Write-offs
Restructuring Cost and Reserve
Special charges, fixed asset impairment charges	0		13
2012 Business Realignment Restructuring Plan | Cost of Sales | Other Restructuring
Restructuring Cost and Reserve
Restructuring reserve period expense	0		1
2012 Business Realignment Restructuring Plan | Operating Expense
Restructuring Cost and Reserve
Special charges	3		78
2012 Business Realignment Restructuring Plan | Operating Expense | Employee Termination Costs
Restructuring Cost and Reserve
Special charges, severance and benefit costs	0		36
2012 Business Realignment Restructuring Plan | Operating Expense | Inventory Valuation Reserve
Restructuring Cost and Reserve
Special charges, inventory obsolescence charges	0		0
2012 Business Realignment Restructuring Plan | Operating Expense | Fixed Asset Write-offs
Restructuring Cost and Reserve
Special charges, fixed asset impairment charges	1		7
2012 Business Realignment Restructuring Plan | Operating Expense | Other Restructuring
Restructuring Cost and Reserve
Restructuring reserve period expense	$2		$35

Special_Charges_Details

Special Charges (Details) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Jan. 03, 2015	Dec. 28, 2013
Field Action Costs | Operating Expense
Purchased In-Process Research And Development (IPR&D) And Special Charges
Legal Fees	$5
March 2010 Securities Class Action
Purchased In-Process Research And Development (IPR&D) And Special Charges
Unusual or Infrequent Item, Insurance Proceeds	10
Manufacturing and Supply Chain Optimization Plan
Purchased In-Process Research And Development (IPR&D) And Special Charges
Special charges	8	32
Restructuring and Related Cost, Expected Cost Remaining	40
Restructuring Reserve	16	20	0
Manufacturing and Supply Chain Optimization Plan | Operating Expense
Purchased In-Process Research And Development (IPR&D) And Special Charges
Special charges	6	25
Manufacturing and Supply Chain Optimization Plan | Cost of Sales
Purchased In-Process Research And Development (IPR&D) And Special Charges
Special charges	2	7
Manufacturing and Supply Chain Optimization Plan | Other Restructuring
Purchased In-Process Research And Development (IPR&D) And Special Charges
Restructuring Reserve	3	6	0
Manufacturing and Supply Chain Optimization Plan | Other Restructuring | Operating Expense
Purchased In-Process Research And Development (IPR&D) And Special Charges
Other Restructuring Costs	3	8
Manufacturing and Supply Chain Optimization Plan | Other Restructuring | Cost of Sales
Purchased In-Process Research And Development (IPR&D) And Special Charges
Other Restructuring Costs	0	0
2012 Business Realignment Restructuring Plan
Purchased In-Process Research And Development (IPR&D) And Special Charges
Special charges	5	108
Restructuring and Related Cost, Expected Cost Remaining	4
Restructuring Reserve	33	38	87
2012 Business Realignment Restructuring Plan | Operating Expense
Purchased In-Process Research And Development (IPR&D) And Special Charges
Special charges	3	78
2012 Business Realignment Restructuring Plan | Cost of Sales
Purchased In-Process Research And Development (IPR&D) And Special Charges
Special charges	2	30
2012 Business Realignment Restructuring Plan | Other Restructuring
Purchased In-Process Research And Development (IPR&D) And Special Charges
Restructuring Reserve	14	12	33
2012 Business Realignment Restructuring Plan | Other Restructuring | Operating Expense
Purchased In-Process Research And Development (IPR&D) And Special Charges
Other Restructuring Costs	2	35
2012 Business Realignment Restructuring Plan | Other Restructuring | Cost of Sales
Purchased In-Process Research And Development (IPR&D) And Special Charges
Other Restructuring Costs	0	1
Field Action Costs | Cost of Sales
Purchased In-Process Research And Development (IPR&D) And Special Charges
Loss Contingency, Loss in Period	($2)

Net_Earnings_Per_Share_Schedul

Net Earnings Per Share - Schedule of Computation of Basic and Diluted Net Earnings Per Share (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014
Earnings Per Share [Abstract]
Net earnings attributable to St. Jude Medical, Inc.	$262	$249
Basic weighted average shares outstanding	283	284.4
Dilution associated with stock-based compensation plans	4.1	4.9
Diluted weighted average shares outstanding	287.1	289.3
Basic net earnings per share attributable to St. Jude Medical, Inc.	$0.93	$0.88
Diluted net earnings per share attributable to St. Jude Medical, Inc.	$0.91	$0.86

Net_Earnings_Per_Share_Details

Net Earnings Per Share (Details)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4.1	2.7

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income and Supplemental Equity Information - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss), net of tax, Beginning Balance	($173)	$46
Other comprehensive income (loss) before reclassifications	-95	10
Amounts reclassified to net earnings from accumulated other comprehensive income	-2	0
Other comprehensive income (loss), net of tax	-97	10
Accumulated other comprehensive income (loss), net of tax, Ending Balance	-270	56
Unrealized gain (loss) on available-for-sale securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss), net of tax, Beginning Balance	15	17
Other comprehensive income (loss) before reclassifications	3	0
Amounts reclassified to net earnings from accumulated other comprehensive income	-2	0
Other comprehensive income (loss), net of tax	1	0
Accumulated other comprehensive income (loss), net of tax, Ending Balance	16	17
Unrealized gain (loss) on derivative instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss), net of tax, Beginning Balance	3	3
Other comprehensive income (loss) before reclassifications	29	0
Amounts reclassified to net earnings from accumulated other comprehensive income	0	0
Other comprehensive income (loss), net of tax	29	0
Accumulated other comprehensive income (loss), net of tax, Ending Balance	32	3
Foreign Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss), net of tax, Beginning Balance	-191	26
Other comprehensive income (loss) before reclassifications	-127	10
Amounts reclassified to net earnings from accumulated other comprehensive income	0	0
Other comprehensive income (loss), net of tax	-127	10
Accumulated other comprehensive income (loss), net of tax, Ending Balance	($318)	$36

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income and Supplemental Equity Information - Schedule of Reclassification out of Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014
Other (income) expense	($3)	$0
Income tax expense	52	53
Net earnings attributable to St. Jude Medical, Inc.	-262	-249
Available-for-sale Securities [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Other (income) expense	-4	0
Income tax expense	2	0
Net earnings attributable to St. Jude Medical, Inc.	($2)	$0

Accumulated_Other_Comprehensiv4

Accumulated Other Comprehensive Income and Supplemental Equity Information - Supplemental Equity Schedule (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$4,244	$4,404
Net earnings	256	239
Other comprehensive income (loss)	-97	10
Cash dividends declared	-81	-77
Repurchases of common stock	-500	-434
Stock-based compensation	17	17
Common stock issued under employee stock plans and other, net	38	60
Tax benefit from stock plans	5	9
Ending Balance	3,882	4,228
Treasury Stock Acquired, Average Cost Per Share	$66.96
Parent [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	4,199	4,231
Net earnings	262	249
Other comprehensive income (loss)	-97	10
Cash dividends declared	-81	-77
Repurchases of common stock	-500	-434
Stock-based compensation	17	17
Common stock issued under employee stock plans and other, net	38	60
Tax benefit from stock plans	5	9
Ending Balance	3,843	4,065
Noncontrolling Interest [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	45	173
Net earnings	-6	-10
Other comprehensive income (loss)	0	0
Cash dividends declared	0	0
Repurchases of common stock	0	0
Stock-based compensation	0	0
Common stock issued under employee stock plans and other, net	0	0
Tax benefit from stock plans	0	0
Ending Balance	$39	$163

Accumulated_Other_Comprehensiv5

Accumulated Other Comprehensive Income and Supplemental Equity Information (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014	Jul. 04, 2015	Jan. 13, 2015	Jun. 07, 2013
Stock Repurchase Program, Authorized Amount				$500
Stock Repurchased During Period, Shares	7.5
Stock Repurchased During Period, Value	500	434
Treasury Stock Acquired, Average Cost Per Share	$66.96
Spinal Modulation [Member]
Noncontrolling Interest, Ownership Percentage by Parent					19.00%
Subsequent Event | Spinal Modulation [Member]
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests			$175
Noncontrolling Interest, Ownership Percentage by Parent			81.00%

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014	Jan. 03, 2015
Income Tax Disclosure [Abstract]
Unrecognized tax benefits	$335		$328
Accrued interest and penalties	$47		$44
Effective Income Tax Rate Reconciliation, Percent	16.90%	18.20%

Fair_Value_Measurements_And_Fi2

Fair Value Measurements And Financial Instruments - Summary Of Components Of Available-For-Sale Securities (Details) (USD $)	Apr. 04, 2015	Jan. 03, 2015
In Millions, unless otherwise specified
Fair Value Disclosures [Abstract]
Adjusted cost	$5	$6
Gross unrealized gains	26	24
Fair value	$31	$30

Fair_Value_Measurements_And_Fi3

Fair Value Measurements And Financial Instruments - Summary of Financial Assets Measured at Fair Value, Recurring Basis (Details) (USD $)	Apr. 04, 2015	Jan. 03, 2015
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	$31	$30
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	598	1,060
Total liabilities	27	50
Recurring | Cash and cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money-market securities	219	729
Recurring | Other current assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	31	30
Foreign currency forward contracts	28
Recurring | Other assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency forward contracts	5
Trading securities	315	301
Recurring | Other liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	27	50
Recurring | Quoted Prices In Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	565	1,060
Total liabilities	0	0
Recurring | Quoted Prices In Active Markets (Level 1) | Cash and cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money-market securities	219	729
Recurring | Quoted Prices In Active Markets (Level 1) | Other current assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	31	30
Foreign currency forward contracts	0
Recurring | Quoted Prices In Active Markets (Level 1) | Other assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency forward contracts	0
Trading securities	315	301
Recurring | Quoted Prices In Active Markets (Level 1) | Other liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Recurring | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	33	0
Total liabilities	0	0
Recurring | Significant Other Observable Inputs (Level 2) | Cash and cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money-market securities	0	0
Recurring | Significant Other Observable Inputs (Level 2) | Other current assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	0
Foreign currency forward contracts	28
Recurring | Significant Other Observable Inputs (Level 2) | Other assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency forward contracts	5
Trading securities	0	0
Recurring | Significant Other Observable Inputs (Level 2) | Other liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Recurring | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	27	50
Recurring | Significant Unobservable Inputs (Level 3) | Cash and cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money-market securities	0	0
Recurring | Significant Unobservable Inputs (Level 3) | Other current assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	0	0
Foreign currency forward contracts	0
Recurring | Significant Unobservable Inputs (Level 3) | Other assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency forward contracts	0
Trading securities	0	0
Recurring | Significant Unobservable Inputs (Level 3) | Other liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$27	$50

Fair_Value_Measurements_And_Fi4

Fair Value Measurements And Financial Instruments - Summary of Level 3 Fair Value Measurements of Contingent Consideration (Details) (Fair Value, Inputs, Level 3, USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Jan. 03, 2015
Nanostim
Fair Value Inputs, Discount Rate	5.00%
Probability of Payment	90.00%
Nanostim | Contingent Consideration Liability
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	27	$50
Income Approach Valuation Technique | Contingent Consideration Liability
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	27
Income Approach Valuation Technique | Nanostim | Contingent Consideration Liability
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	27

Recovered_Sheet1

Fair Value Measurements and Financial Instruments - Unobservable Input Reconciliation of Contingent Consideration Liability (Details) (Nanostim, Fair Value, Inputs, Level 3, Contingent Consideration Liability, USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015
Nanostim | Fair Value, Inputs, Level 3 | Contingent Consideration Liability
Contingent Consideration Liability [Roll Forward]
Beginning balance	$50
Change in Fair Value of Contingent Consideration	-23
Ending balance	$27

Recovered_Sheet2

Fair Value Measurements and Financial Instruments (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015	Mar. 29, 2014	Jan. 03, 2015
Fair Value Inputs, Liabilities, Quantitative Information
Fair Value, Estimate Not Practicable, Cost Method Investments	$72		$71
Fixed rate debt obligations fair value disclosure	2,386
Fixed rate debt obligations carrying value	2,271
Other debt carrying value	1,233
cash equivalents at carrying value excluding money market securities	476		713
Fixed Asset Write-offs | 2012 Business Realignment Restructuring Plan
Fair Value Inputs, Liabilities, Quantitative Information
Other Asset Impairment Charges	$1	$1

Derivative_Financial_Instrumen2

Derivative Financial Instruments Summary of Derivative Instruments (Gain) Loss (Details) (Foreign Exchange Forward [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015
Cost of Sales | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member]
Derivative Instruments, (Gain) Loss [Line Items]
(Gain) loss recognized in Other Comprehensive Income	($34)
(Gain) loss reclassified from Accumulated Other Comprehensive Income	0
(Gain) loss on derivatives excluded from effectiveness testing	0
Other Nonoperating (Income) Expense [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, (Gain) Loss [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, (Gain) Loss, Net	($9)

Derivative_Financial_Instrumen3

Derivative Financial Instruments Schedule of Fair Value of Derivative Instruments (Details) (USD $)	Apr. 04, 2015
In Millions, unless otherwise specified
Derivatives, Fair Value [Line Items]
Fair value of derivative instruments	$33
Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Fair value of derivative instruments	33
Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member] | Other current assets [Member]
Derivatives, Fair Value [Line Items]
Fair value of derivative instruments	24
Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivatives, Fair Value [Line Items]
Fair value of derivative instruments	5
Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member] | Other current assets [Member]
Derivatives, Fair Value [Line Items]
Fair value of derivative instruments	$4

Derivative_Financial_Instrumen4

Derivative Financial Instruments Schedule of Offsetting Derivative Assets (Details) (USD $)	Apr. 04, 2015
In Millions, unless otherwise specified
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Gross amount of derivatives subject to master netting agreements	$9
Gross amount of derivatives not subject to master netting agreements	24
Gross amount of derivatives	33
Gross amount of eligible offsetting derivative liabilities	0
Gross amount of cash collateral received not offset	0
Net amount of derivatives subject to master netting agreements	9
Net amount of derivatives not subject to master netting agreements	24
Net amount of derivatives	$33

Derivative_Financial_Instrumen5

Derivative Financial Instruments (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2015
Derivatives, Fair Value [Line Items]
Unrealized gains expected to be reclassed to earnings over the next 12 months	$22
Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Gross notional amount of derivative	190
Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member]
Derivatives, Fair Value [Line Items]
Gross notional amount of derivative	1,100
After-tax net unrealized gain related to foreign currency forward contracts recorded in accumulated other comprehensive income	$29